RE: RNS15 Oct 2024 07:22
So Michelle is well connected to Astra Zeneca.
"Prior to that, she established an immuno-oncology preclinical modelling group supporting projects across the Medimmune and AstraZeneca portfolio and held Discovery Project Leader roles for Imfinzi®, an approved anti-PD-L1 antibody, and volrustomig, an anti- PD-1/CTLA-4 bispecific antibody."
MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion.